Project Grant R01CA311335
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $463K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through July 31, 2032. The award supports research into new approaches for targeting cell cycle proteins in cancer treatment, specifically focusing on cyclin-dependent kinase (CDK) inhibitor development and therapeutic applications. The research addresses critical...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $721,653 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective June 5, 2026, with a completion date of May 31, 2031. The research focuses on identifying protein O-mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade gliomas (PLGGs), the most common solid tumors in childhood. The project deliverables include fundamental...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant totaling $645,102 under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on cell cycle control mechanisms. The five-year award, which commenced on July 1, 2026 and concludes on June 30, 2031, supports investigation into the molecular mechanisms governing WEE1 kinase—specifically how this regulatory protein transitions between functioning as...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $134,919 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective June 11, 2026, with completion targeted for May 31, 2028. This award supports biomedical research training and career development focused on cancer research aligned with the National Cancer Program's strategic priorities. The institute will leverage this funding to provide research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute a Project Grant of $683,075 under the Cancer Cause and Prevention Research program (CFDA 93.393), with an award date of March 24, 2026, and a completion date of February 28, 2031. This research initiative, titled "TIRR/53BP1 Complex Regulates Mitotic Fidelity and Immune-Mediated Radiation Response," investigates the mitotic functions of 53BP1, a protein critical to genome stability...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $341,280 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2025 through June 30, 2027. This award supports a K99/R00 Pathway to Independence research project investigating the role of histone cleavage in triple-negative breast cancer (TNBC), with emphasis on understanding the KDM4C histone demethylase protein and its tumorigenic mechanisms....
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $638,771 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning June 1, 2026, with a completion date of May 31, 2031. This five-year award funds fundamental research investigating non-canonical functions of the mitochondrial fission protein DRP1 (Dynamin-Related Protein 1) in high-grade serous ovarian cancer (HGSOC). The research examines how a splice variant of...